Cleo kicks off long path towards FDA approval for ovarian cancer blood tests

Cleo Diagnostics has announced it's commenced the FDA regulatory process to get into the US market…

Cleo Diagnostics reports its ovarian cancer blood tests superior to ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.